Treatment choices primarily rely on patients’ preferences and clinical assessments made by surgeons, while the survival outcomes of T2N1M0 stage HR + /HER2- breast cancer patients undergoing NACT compared with ACT remain uncertain [16]. This evidence concerns the gene ERBB2 and breast carcinoma.